Literature DB >> 6249243

Prepubertal vaccination of mice against experimental infection of the genital tract with type 2 herpes simplex virus.

G R Skinner, D R Williams, A W Moles, A Sargent.   

Abstract

Pre-pubertal immunisation of mice with a formalin-inactivated type 1 and 2 herpes simplex virus vaccine conferred a level of life-long protection against primary type 2 genital infection. Protection levels were better with type 1 vaccine and strikingly influenced by vaccine dosage where a one-hundred-fold reduction from the standard vaccine dosage diminished protection to insignificant levels. Vaccine efficacy was not significantly affected by the method of virus inactivation, the number of immunisations or the age of the mouse at immunisation. Vaccination conferred better protection than previous type 2 genital infection; this may be a consequence of a higher antigenic dose, more acceptable antigenic presentation or to a perversion of the immune response in a latently infected animal to homologous virus challenge.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6249243      PMCID: PMC7101888          DOI: 10.1007/bf01320618

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  29 in total

1.  Interaction of herpes virus and HeLa cells: comparison of cell killing and infective center formation.

Authors:  J T VANTSIS; P WILDY
Journal:  Virology       Date:  1962-06       Impact factor: 3.616

2.  Latent infection of sensory ganglia with herpes simplex virus: efficacy of immunization.

Authors:  R W Price; M A Walz; C Wohlenberg; A L Notkins
Journal:  Science       Date:  1975-05-30       Impact factor: 47.728

3.  Effect of immunization on acute and latent infections of vaginouterine tissue with herpes simplex virus types 1 and 2.

Authors:  M A Walz; R W Price; K Hayashi; B J Katz; A L Notkins
Journal:  J Infect Dis       Date:  1977-05       Impact factor: 5.226

4.  Herpes simplex viruses: discrimination of types and correlation between different characteristics.

Authors:  G Plummer; C R Goodheart; M Miyagi; G R Skinner; M E Thouless; P Wildy
Journal:  Virology       Date:  1974-07       Impact factor: 3.616

5.  Immunogenic properties of formalin herpes antigen prepared from cell cultures.

Authors:  R Benda; V Dbalý
Journal:  J Hyg Epidemiol Microbiol Immunol       Date:  1973

Review 6.  Infection with herpes-simplex viruses 1 and 2. II.

Authors:  A J Nahmias; B Roizman
Journal:  N Engl J Med       Date:  1973-10-04       Impact factor: 91.245

7.  Differentiation between type 1 and type 2 strains of herpes simplex virus by an indirect immunofluorescent technique.

Authors:  L Geder; G R Skinner
Journal:  J Gen Virol       Date:  1971-08       Impact factor: 3.891

8.  Precipitating antibodies to herpes simplex virus in human sera: prevalence of antibody to common antigen (band II).

Authors:  G R Skinner; J Taylor; J Edwards
Journal:  Intervirology       Date:  1974       Impact factor: 1.763

9.  Seroepidemiologic studies of herpesvirus type 2 and carcinoma of the cervix. IV. Dysplasia and carcinoma in situ.

Authors:  E Adam; R H Kaufman; J L Melnick; A H Levy; W E Rawls
Journal:  Am J Epidemiol       Date:  1973-08       Impact factor: 4.897

10.  Efficacy of herpes simplex virus type 1 immunization in protecting against acute and latent infection by herpes simplex virus type 2 in mice.

Authors:  R R McKendall
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

View more
  6 in total

1.  Report of twelve years experience in open study of Skinner herpes simplex vaccine towards prevention of herpes genitalis.

Authors:  G R Skinner; C Fink; J Melling; C Wiblin; B Thornton; J Hallworth; W Gardner; P McLeish; C Hartley; A Buchan
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

2.  The influence of different modes of immunization on the experimental genital herpes simplex virus infection of mice.

Authors:  K E Schneweis; J Gruber; J Hilfenhaus; A Möslein; M Kayser; M H Wolff
Journal:  Med Microbiol Immunol       Date:  1981       Impact factor: 3.402

3.  Immunogenicity and protective efficacy in a rhesus monkey model of vaccine Ac NFUi(S-) MRC against primary type 2 herpes simplex virus infection.

Authors:  G R Skinner; A Buchan; D Williams; J Marsden; C Hartley; G Wilbanks; M Turyk; E S Namkoong
Journal:  Br J Exp Pathol       Date:  1982-08

4.  The preparation, efficacy and safety of 'antigenoid' vaccine NFU1 (S-L+) MRC toward prevention of herpes simplex virus infections in human subjects.

Authors:  G R Skinner; A Buchan; C E Hartley; S P Turner; D R Williams
Journal:  Med Microbiol Immunol       Date:  1980       Impact factor: 3.402

5.  Experimental ulcerative herpetic keratitis. IV. Preliminary observations on the efficacy of a herpes simplex subunit vaccine.

Authors:  C A Carter; C E Hartley; G R Skinner; S P Turner; D L Easty
Journal:  Br J Ophthalmol       Date:  1981-10       Impact factor: 4.638

6.  Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.

Authors:  R J Klein; E Buimovici-Klein; H Moser; R Moucha; J Hilfenhaus
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.